RogCon Biosciences Launches with Late-Breaking Presentation on SCN2A Epilepsy at the 2018 AES Meeting

SAN DIEGO, Dec. 1, 2018 /PRNewswire/ -- RogCon Biosciences (RogCon), a biotechnology company focused on discovering and developing novel therapeutics for children suffering from SCN2A mutations, today announced preclinical data in a late-breaking poster presentation at the 2018 American...

from PR Newswire: https://ift.tt/2DZr8uT